E
BLPH

Ergoteles’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Ergoteles’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,891
Closed -$13.4K – 2021
2022
Q4 		$13.4K Buy
+14,891
New +$15.2K ﹤0.01% 1361
2021
Q3 		– Sell
-13,800
Closed -$67K – 1890
2021
Q2 		$67K Buy
+13,800
New +$61.9K ﹤0.01% 1433

Other funds holding BLPH

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's BLPH Position: Q1 2023 in Review

Ergoteles sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2023, closing a stake of 14,891 shares — an estimated $13.4K sold.

Ergoteles first reported a position in BLPH in Q2 2021 and held it in 2 quarters. The position peaked at $67K in Q2 2021. 19 funds tracked by Wall St. Rank hold BLPH as of Q1 2023.

  • Ergoteles reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 14,891 Bellerophon Therapeutics, Inc. shares in Q1 2023, an estimated $13.4K.
  • Ergoteles first reported a position in Bellerophon Therapeutics, Inc. in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Bellerophon Therapeutics, Inc. position peaked at $67K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.